Clinical Trial Update: Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial testing estramustine, etoposide, and paclitaxel for hormonally responsive prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Estramustine (estramustine)
• Etoposide (Etoposide)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED